Tumor cell death in orthotopic breast cancer model by NanoALA: a novel perspective on photodynamic therapy in oncology.
Laise Rodrigues de AndradeAntonio C TedescoFernando L PrimoGabriel R FariasJaqueline Rodrigues da SilvaJoão Pf LongoMarcos C de AlmeidaPaulo En de SouzaRicardo B de AzevedoWillie O PinheiroZulmira Gm LacavaPublished in: Nanomedicine (London, England) (2020)
Aim: Nano-5-aminolevulic acid (NanoALA)-mediated photodynamic therapy (PDT), an oil-in-water polymeric nanoemulsion of ALA, was evaluated in a murine model of breast cancer. Materials & methods: Analysis of ALA-derived protoporphyrin IX production and acute toxicity test, biocompatibility and treatment efficacy, and long-term effect of NanoALA-PDT on tumor progression were performed. Results: The nanoformulation favored the prodrug uptake by tumor cells in a shorter time (1.5 h). As a result, the adverse effects were negligible and the response rates for primary mammary tumor control were significantly improved. Tumor progression was slower after NanoALA-PDT treatment, providing longer survival. Conclusion: NanoALA is a good proactive drug candidate for PDT against cancer potentially applied as adjuvant/neoadjuvant intervention strategy for breast cancer.
Keyphrases
- photodynamic therapy
- fluorescence imaging
- cell death
- poor prognosis
- randomized controlled trial
- drug delivery
- early stage
- liver failure
- lymph node
- cancer therapy
- palliative care
- rectal cancer
- radiation therapy
- squamous cell carcinoma
- long non coding rna
- hepatitis b virus
- combination therapy
- intensive care unit
- papillary thyroid
- emergency department
- extracorporeal membrane oxygenation
- electronic health record
- adverse drug
- acute respiratory distress syndrome